VERMOX Drug Patent Profile

When do Vermox patents expire, and what generic alternatives are available?

Vermox is a drug marketed by Janssen Pharms and is included in two NDAs.

The generic ingredient in VERMOX is mebendazole. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mebendazole profile page.

Summary for VERMOX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	6
Patent Applications:	3,663
What excipients (inactive ingredients) are in VERMOX?	VERMOX excipients list
DailyMed Link:	VERMOX at DailyMed

Recent Clinical Trials for VERMOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RDD Pharma Ltd	Phase 2
Noguchi Memorial Institute for Medical Research	Phase 4
Ghana Health Services	Phase 4

See all VERMOX clinical trials

Pharmacology for VERMOX

Drug Class

Anthelmintic

US Patents and Regulatory Information for VERMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	017481-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	208398-001	Oct 19, 2016		DISCN	Yes	No

Expired US Patents for VERMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	VERMOX	mebendazole	TABLET, CHEWABLE;ORAL	017481-001	Approved Prior to Jan 1, 1982

International Patents for VERMOX

See the table below for patents covering VERMOX around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2029637	METHYL-N-5 (6)-ACYL-2-BENZIMIDAZOLYLCARBAMATE
France	2052988
Austria	307798
Belgium	752089
Malaysia	7300477	NOVEL ALKYL ESTERS OF N-[5(6)-ACYL-2-BENZIMIDAZOLYL]CARBAMIC ACIDS AND A PROCESS FOR THE PREPARATION THEREOF
Finland	52719
South Africa	7004191

VERMOX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VERMOX

Introduction to VERMOX

VERMOX, a brand name for the anthelmintic drug mebendazole, is a crucial medication in the global fight against intestinal worms, particularly soil-transmitted helminths (STH). Developed by Janssen Pharmaceutical Companies, a part of Johnson & Johnson, VERMOX has been a cornerstone in public health initiatives aimed at eliminating neglected tropical diseases (NTDs).

Market Size and Growth

The global mebendazole market, which includes VERMOX, has been experiencing significant growth. As of 2023, the market size was valued at approximately USD 117.6 million to USD 231.8 million, depending on the source[3][5].

• Forecasted Growth: The market is expected to reach USD 173 million by 2030, growing at a CAGR of 5.6% from 2024 to 2030[3].
• Alternative Projections: Another estimate suggests the market could reach USD 470.2 million by 2031, with a higher CAGR of 8.2% from 2024 to 2031[5].

Key Market Drivers

Several factors are driving the growth of the mebendazole market, including:

Rising Prevalence of Parasitic Infections

The increasing prevalence of parasitic infections globally, especially in developing countries, has heightened the demand for effective anthelmintic drugs like VERMOX[5].

Deworming Programs

Government and international health organization initiatives to implement deworming programs in schools and communities have significantly boosted the demand for mebendazole. These programs aim to reduce the burden of intestinal worms, which are particularly detrimental to children's health and development[4].

Technological Advancements

Advances in drug formulation, such as the development of chewable tablets and oral suspensions, have improved the efficacy and convenience of mebendazole, making it more appealing to patients and healthcare providers[4].

Expanding Healthcare Infrastructure

The growth in healthcare infrastructure, especially in emerging nations, has increased access to healthcare services and driven the demand for mebendazole[5].

Market Segmentation

The mebendazole market is segmented in several ways:

By Application

• Intestinal Worm Infections: This includes treatments for ascariasis, pinworm infections, and whipworm infections.
• Hydatid Disease: Though less common, mebendazole is also used to treat hydatid disease[5].

By Product

• Tablets: Traditional solid tablets have been widely used.
• Chewable Tablets: The new pediatric formulation of VERMOX, prequalified by the WHO, is designed for children as young as one year old.
• Oral Suspension: Another form that enhances the ease of administration, especially for children[4][5].

By Geography

• North America: A mature market with established healthcare systems.
• Europe: Similar to North America, with a strong focus on public health initiatives.
• APAC (Asia-Pacific): A region with high growth potential due to increasing healthcare spending and expanding infrastructure.
• Middle East & Africa: Regions with significant public health challenges related to intestinal worms[5].

Key Players and Competitive Landscape

The mebendazole market is dominated by several key players:

• Johnson & Johnson: Through its Janssen Pharmaceutical Companies, Johnson & Johnson is a leading provider of VERMOX and has a long-standing commitment to donating the medication to at-risk populations[2][4].
• Sanofi: Another major pharmaceutical company involved in the production and distribution of mebendazole.
• Teva Pharmaceutical Industries Ltd.: Known for its generic and branded medications, including mebendazole.
• Bayer AG: A global pharmaceutical company with a diverse portfolio that includes anthelmintic drugs.
• GlaxoSmithKline plc: A major player in the pharmaceutical industry with a range of products, including those for parasitic infections[5].

Donation Programs and Public Health Impact

Johnson & Johnson's donation program for VERMOX has been instrumental in the global fight against intestinal worms. Here are some key highlights:

• Extended Donation Commitment: Johnson & Johnson has extended its donation program through 2025, ensuring an additional 1 billion doses of VERMOX will be delivered to at-risk children in developing countries[2].
• WHO Prequalification: The new pediatric formulation of VERMOX has been prequalified by the WHO, ensuring its broad deployment in high-burden countries[4].
• Impact on Public Health: These donations have already resulted in the delivery of more than 1.4 billion doses to approximately 800 million children worldwide, significantly reducing the prevalence of intestinal worms and their debilitating effects on children's health and development[4].

Financial Trajectory

The financial trajectory of the mebendazole market, and thus VERMOX, is positive and growth-oriented:

• Revenue Growth: The market is expected to grow from USD 117.6 million in 2023 to USD 173 million by 2030, or alternatively to USD 470.2 million by 2031, depending on the projections[3][5].
• CAGR: The compound annual growth rate (CAGR) is estimated to be around 5.6% to 8.2% during the forecast period, indicating a robust growth trajectory[3][5].

Challenges and Opportunities

While the market for VERMOX is growing, there are several challenges and opportunities to consider:

Challenges

• Regulatory Approvals: Ensuring continuous regulatory approvals and compliance is crucial.
• Product Safety and Efficacy: Monitoring for any safety concerns or efficacy issues, especially with prolonged use or higher doses[2][4].
• Manufacturing and Distribution: Maintaining efficient manufacturing and distribution channels to meet the growing demand.

Opportunities

• Expanding Healthcare Access: Increasing access to healthcare services in emerging nations presents a significant opportunity for market expansion.
• Technological Innovations: Continued advancements in drug formulation and delivery technologies can enhance the market appeal of VERMOX.
• Public-Private Partnerships: Collaborations with government and international health organizations can further amplify the impact of deworming programs and increase market demand[5].

Key Takeaways

• The mebendazole market, driven by the demand for VERMOX, is expected to grow significantly over the next few years.
• Key drivers include the rising prevalence of parasitic infections, deworming programs, and technological advancements in drug formulation.
• Johnson & Johnson's donation programs have been critical in reducing the burden of intestinal worms globally.
• The market is segmented by application, product form, and geography, with several major pharmaceutical companies playing key roles.
• Despite challenges, the financial trajectory of the market is positive, with a robust CAGR projected during the forecast period.

FAQs

Q: What is the expected CAGR of the mebendazole market from 2024 to 2030? A: The expected CAGR is around 5.6% to 8.2%, depending on the source[3][5].

Q: How many doses of VERMOX has Johnson & Johnson donated to date? A: Johnson & Johnson has donated more than 1.4 billion doses of VERMOX to approximately 800 million children worldwide[4].

Q: What is the significance of the new pediatric formulation of VERMOX? A: The new pediatric formulation, VERMOX CHEWABLE, is designed for children as young as one year old and has been prequalified by the WHO, making it easier to administer and safer for younger children[4].

Q: Which regions are expected to dominate the global mebendazole market? A: The APAC region is expected to show high growth potential due to increasing healthcare spending and expanding infrastructure[5].

Q: What are the main factors driving the growth of the mebendazole market? A: The main factors include the rising prevalence of parasitic infections, deworming programs, technological advancements in drug formulation, and expanding healthcare infrastructure[5].

Sources

1. Cognitivemarketresearch.com: Vermox Market Report 2024 (Global Edition)
2. Johnson & Johnson: Johnson Extends Long-Standing Donation Program to Support Global Effort to Tackle Intestinal Worms
3. Valuates.com: Global Mebendazole Market Research Report 2024
4. Johnson & Johnson: New Pediatric Formulation of Janssen’s Treatment for Intestinal Worms Achieves World Health Organization Prequalification
5. Marketresearchintellect.com: Mebendazole Market Size and Projections